A Phase 4 interventional study of Fucidin® cream in Impetigo, sponsored by LEO Pharma. Terminated at 2 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by LEO Pharma · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients.
To assess the validity of in vitro susceptibility-testing of S. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with Fucidin® cream.
To investigate the genetic relationship between S. aureus-strains isolated from impetigo patients.
30 studies on the registry are indexed under Impetigo; 3 are open to participants now.
This study's enrollment of 58 is below the median of 255 across 24 interventional studies indexed under Impetigo.
Browse Impetigo studies →LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Fucidin® cream
Drug: Fucidin® cream
Number of Patients With Clinical Success (Marked Improvement or Completely Cleared) and Bacteriological Success (Eradication) at End of Treatment (EOT).
Time frame: EOT: Visit at Day 25
Number of Patients With Clinical Success at Visit 2
Time frame: Visit 2: Day 4
Number of Patients With Clinical Success at Visit 3
Time frame: Visit 3: Day 11
Number of Patients With Clinical Success at EOT
Time frame: EOT: Visit at day 25
Number of Patients With Bacteriological Success at Visit 2
Time frame: Visit 2: Day 4
Number of Patients With Bacteriological Success at Visit 3
Time frame: Visit 3: Day 11
Number of Patients With Bacteriological Success at EOT
Time frame: EOT: Visit at day 25
The Actual Change in Total Severity Score From Baseline to End of Treatment (LOCF).
Total Severity Score is the sum of scores for the following 5 signs: Pustules/infected bullae, erythema, infiltration/induration, erosions and crusting. Each sign is assessed using a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe involvement. Minimum Total Severity score is 0, maximum score is 15.
Time frame: EOT: Visit at day 25
| Milestone | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Started | 42 | 16 |
| Completed | 42 | 16 |
| Not completed | 0 | 0 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Clinical and bacteriological success | 16 | 1 |
| Clinical and bacteriological failure | 17 | 12 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 18 | 2 |
| Failure | 22 | 14 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 27 | 7 |
| Failure | 7 | 3 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 27 | 7 |
| Failure | 13 | 9 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 6 | 0 |
| Failure | 27 | 13 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 17 | 1 |
| Failure | 10 | 5 |
| Participants | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Success | 17 | 1 |
| Failure | 16 | 12 |
Total Severity Score is the sum of scores for the following 5 signs: Pustules/infected bullae, erythema, infiltration/induration, erosions and crusting. Each sign is assessed using a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe involvement. Minimum Total Severity score is 0, maximum score is 15.
| Units on a scale | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| The Actual Change in Total Severity Score From Baseline to End of Treatment (LOCF). | -3.9 ± 3.5 | -1.2 ± 4.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fucidin® Cream | — | 0/40 (0%) | 5/40 (12.5%) |
| Fucidin® Cream Vehicle | — | 0/16 (0%) | 4/16 (25%) |
| Event | Fucidin® Cream | Fucidin® Cream Vehicle |
|---|---|---|
| Infections and infestationsInfections and infestations | 3/40 | 4/16 |
| Gastrointestinal disordersGastrointestinal disorders | 1/40 | 0/16 |
| Infections andSkin and subcutaneous tissue disorders | 1/40 | 0/16 |
| Age, Categorical(Participants) | Fucidin® Cream | Fucidin® Cream Vehicle | Total |
|---|---|---|---|
| <=18 years | 42 | 16 | 58 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Fucidin® Cream | Fucidin® Cream Vehicle | Total |
|---|---|---|---|
| Mean | 4.8 ± 2.7 | 6.3 ± 2.9 | 5.2 ± 2.8 |
| Sex: Female, Male(Participants) | Fucidin® Cream | Fucidin® Cream Vehicle | Total |
|---|---|---|---|
| Female | 18 | 8 | 26 |
| Male | 24 | 8 | 32 |
| Region of Enrollment(participants) | Fucidin® Cream | Fucidin® Cream Vehicle | Total |
|---|---|---|---|
| Sweden | 32 | 15 | 47 |
| Norway | 10 | 1 | 11 |
| S.aureus susceptible to fusidic acid(S. aureus) | Fucidin® Cream | Fucidin® Cream Vehicle | Total |
|---|---|---|---|
| S. aureus susceptible to fusidic acid | 12 | 4 | 16 |
| S. aureus resistant to fusidic acid | 18 | 8 | 26 |
| No S. aureus isolated | 12 | 4 | 16 |
Plan to share: No
The record gives a start of May 2004, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fusidic Acid